A Gene-Based Classification of Primary Adrenocortical Hyperplasias

Authors
Fady Hannah-Shmouni, Constantine A. Stratakis

Affiliation
Section on Endocrinology & Genetics (SEGEN), NICHD, Bethesda, MD, USA

Key words
adrenal hyperplasia, Cushing syndrome, genetics, Carney complex, cyclic AMP, PPNAD, PMAH

received 11.11.2019
accepted 15.01.2020

Bibliography
DOI https://doi.org/10.1055/a-1107-2972
Horm Metab Res 2020; 52: 133–141
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0018-5043

Correspondence
Constantine A. Stratakis MD, D(Med) Sci., PhD(hc)
Senior Investigator and Scientific Director, Section on Endocrinology & Genetics (SEGEN), The Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health
Building 10, CRC, Room 1-3330, 10 Center Dr., MSC1103
Bethesda
20892 Maryland
USA
Tel: +1 301 496 4686/496 6683, Fax: +1 301 402 0574/480 0378
stratakc@mail.nih.gov

Introduction
Adrenocorticotropin (ACTH)-independent, primary adrenocortical tumors and hyperplasias are neoplasms of the adrenal cortex that arise due to perturbations in various key molecular pathways; for benign tumors cyclic AMP (cAMP)-signaling is the main pathway (Fig. 1) [1]. Traditionally, ACTH-independent adrenocortical tumors and hyperplasias were classified into three major categories as adenomas, hyperplasias, and carcinomas [2]. This classification is non-specific for several reasons. First, it does not factor the various genetic defects and hormone functionality of these lesions. Second, causative genes in the predisposition and/or development of these lesions are increasing in number owing to the rapid adoption of genetic technologies in routine clinical practice and translational research. Third, these lesions may arise in the context of familial or syndromic conditions, which require careful phenotyping and genetic counseling of at risk individuals or their relatives. Thus, a more robust and specific classification system is required.

The various types of adrenocortical tumors and hyperplasias, their histology and genetics are described in Table 1. Translational research of primary adrenocortical hyperplasias have identified key molecular pathways involved in tumor formation (Fig. 1) [3, 4]. The initial discovery of disease-causing activating variants in GNAS, which encodes the alpha subunit (Gsα) of the stimulatory guanine nucleotide-binding protein (Fig. 1) in primary adrenocortical hyperplasia of patients with McCune–Albright syndrome (MAS), was critical in establishing that cAMP signaling is involved
Molecular Pathways in Primary Adrenocortical Hyperplasias

The major molecular pathway that is perturbed in primary adrenocortical cortisol-producing neoplasms is the cAMP-signaling pathway (Fig. 1). Briefly, the G-protein coupled receptor for ACTH (ACTHR), also known as melanocortin 2 receptor (MC2R), is a seven-transmembrane receptor that undergoes extensive conformational changes in response to its ligand, ACTH (Fig. 1). This leads to activation of adenylyl cyclase (AC) through the G proteins and the generation of cyclic AMP, activating protein kinase A (PKA), a holoenzyme that consists of a tetramer of two homo- or heterodimers regulatory subunits (R1α, R1β, R2α, and R2β), and catalytic subunits (Ca, Cβ, Cγ, and PRKX) that are encoded by the respective genes [13]. This in turn enables phosphorylation of PKA targets, including gene expression to mediate cell growth, differentiation and hormone production (e.g., cortisol and its pre-cursors). As shown in Fig. 1, genetic alterations in key genes of the cAMP-signaling pathway lead to the formation of various primary adrenocortical lesions.

Classification of Primary Adrenocortical Hyperplasia

In 2007, a comprehensive classification of ACTH-independent adrenocortical hyperplasia was proposed [2]. On histopathology,
Macronodular adrenocortical hyperplasia

PBMAH is the most common subtype of macronodular adrenocortical hyperplasia. This condition is often bilateral and affects the adult population [16]. First described in 1964 [17], PBMAH has been referred to by many names which continues to pose confusion in medical literature, including massive macronodular adrenocortical disease (MMAD), bilateral macronodular adrenal hyperplasia (BMAH), ACTH-independent macronodular adrenocortical hyperplasia (AIMAH), autonomous macronodular adrenal hyperplasia (AMAD), primary macronodular adrenal hyperplasia (PMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and “giant” or “huge” macronodular adrenal disease [18]. Asynchronous involvement of only one adrenal gland in PBMAH is rare [19]. After the recent discovery of a local intra-adrenal secretion of ACTH with an autocrine/paracrine effect on glucocorticoid secretion [20, 21] the term PBMAH has been favored, as a form of pituitary ACTH-independent hyperplasia.

On imaging, PBMAH is characterized by bilateral adrenal enlargement that is often multinodular. On pathology, PBMAH is represented by a dominant or multiple yellowish nodules (similar in color to normal adrenal tissue) with intervening hyperplasia or atrophy, consisting of lipid-rich and poor cells that form several island-like structures, devoid of dark pigmentation [17]. On histology, PBMAH can be divided into two types: Type 1 manifests with multiple nodules or discrete adenomas of various sizes (but typically over 1 cm) and inter nodular atrophy, while those with Type 2 have diffuse hyperplasia without inter nodular atrophy [22]. The combined weight of both adrenals in PBMAH ranges from 55–90 grams [16, 23].

PBMAH is a clinically heterogeneous disorder that is often associated with subclinical glucocorticoid and/or mineralocorticoid secretion in adults over a number of years. PBMAH may also manifest clinically with overt Cushing syndrome, associated with cortisol (or its precursor steroids) and/or other steroid hormone (including aldosterone) excess [22, 24]. Glucocorticoid and other steroid hormone secretion may be mediated by non-mutated but aberrantly expressed receptors through vasopressin, serotonin, catecholamines, gastric inhibitory polypeptide (GIP), luteinizing hormone, or autocrine/paracrine ACTH stimulation [25–28].

PBMAH was initially mostly reported as a sporadic disease but was found to be inherited in a dominant manner in several families. Recently, the tumor suppressor ARMC5 was implicated in 20–50% of apparent sporadic and familial PBMAH cases, where both alleles carried one germline and one somatic disease-causing variant each [12, 19, 29, 30]. A second somatic event is required to mediate tumorigenesis and polycystic nodularity, either 16p loss of heterozygosity or a somatic hit in ARMC5 [31]. Interestingly, each nodule in PBMAH may harbor a ‘private’ disease-causing variant, thus tissues have defects that completely inactivate ARMC5 [31].

Other genetic defects have been implicated in the pathogenesis of PBMAH, including the somatic activating variant of GNAS at codon Arg (201) without features of MAS [22, 32], the germline p.R867G variant of PDE11A in a patient with familial PBMAH [22], the several disease-causing germline variants of PDEB8 [33], and germline variants in FH, MEN1, and APC in the context of familial syndromes as detailed below in this review [22, 32]. Very rarely, patients with familial PBMAH may carry germline duplications of PRKACA resulting in copy number gains [34, 35]. Possible disease-causing variants of the M2CR gene have also been reported in PBMAH [36]. A number of genomic/transcript abnormalities have been reported in PBMAH, including losses in 20q13 and 14q23 [7], overexpression of WISP2, BCL2, EZF1, EGF, c-KIT, MYB, PRKACA, and CTNNB1, which implicates various aberrant oncogenic pathways in nodular polyclonality and growth [37]. Chromatin deregulation of DOTL and HDAC9, implicated in regulating gene transcription and cell proliferation have also been implicated in the pathogenesis of PBMAH [38].

Other rare subtypes of ACTH-independent macronodular adrenocortical hyperplasia include primary bimorphic adrenocortical disease (PBAD, as seen in MAS) and food-dependent Cushing syndrome (FDCS, also known as GIP-dependent Cushing syndrome). PBAD due to MAS is a congenital disorder that presents in the infantile period with severe hypercortisolism due to nodular adrenocortical hyperplasia with sharply defined zones of cortical atrophy that give the cortex a bimorphic appearance [5, 39]. PBAD is caused by constitutive activation of the cAMP-signaling pathway from postzygotic gain-of-function variants in GNAS, within exon 8 of the Gsα subunit (Fig. 1) [7]. Moreover, the differential diagnosis of hypercortisolism in patients with MAS also includes bilateral “atypical” adenomas [40], isolated bilateral hyperplasia [41], and hyperplasia with spontaneous resolution [42] or improvement after unilateral adrenalectomy [43, 44].

In a rare form of FDCS, glucocorticoid excess is driven by aberrant glucose-dependent insulinolectopic polypeptide receptor (GIPR) expression that arise from somatic duplications (within the adrenal lesions) in chromosome region 19q13.32 containing the GIPR locus [45]. GIP-dependent PBMAH should be distinguished from FDCS. The differential histopathological characteristics and features of these lesions are summarized in Table 1.

Micronodular adrenocortical hyperplasia

Of the micronodular variety, PPNAD which is congenital and often bilateral is the most common subtype. PPNAD is either pigmented (c-PPNAD) as seen in CNC, or isolated (i-PPNAD); this condition has also been referred to non-specific nomenclatures, including macronodular adrenal disease and microadenomatosis or primary adren-
c-PPNAD is primarily caused by inactivating variants in PRKACA. It should be noted that CNC may also be caused by PRKACA duplication (19p13.1) [9]. Rarely, CNC is caused by a yet to be identified gene that is mapped to chromosome 2 (CNC2 locus on 2p16) [48]. Activation of the cAMP pathway in PPNAD leads to upregulation of serotonin (5-HT) synthesizing enzyme tryptophan hydroxylase (TPH) and its receptors (5-HT4, 5-HT6, and 5-HT7).

It should be noted that CNC may also be caused by PRKACA amplification (CNC3 locus) [8]; PRKACA codes for the PKA catalytic subunit beta (CB) (Fig. 1). Defects in PRKACA have not been linked to PPNAD despite its association with other manifestations of CNC.

i-PPNAD is regarded as a separate entity from PPNAD, with earlier onset of clinical manifestations, cyclicity of hypercortisolism and/or mineralocorticoid excess. Associated with MEN-1, FAP, MAS, HLRCS, isolated (AD) Most lesions have aberrant GPCRs (vasopressin, serotonin, catecholamines, GIP, luteinizing hormone) PMAH carry the ability of intra-adrenal production of ACTH with an autocrine/paracrine effect on glucocorticoid or mineralocorticoid production.

PPNAD was coined by Dr J. Aidan Carney (Mayo Clinic, Rochester, Minnesota, United States) in 1984 [47]. PPNAD presents as multiple, small, pigmented nodules (~6 mm in size) with inter- nodular cortical atrophy [18]. Unlike in PMAH, the adrenal glands in PPNAD have several pathognomonic features including abnormal adrenal contour on imaging, smaller in size than in PBMHAH (15–25 grams), darkly pigmented (brown or black nodules) and there is adrenal contour on imaging, smaller in size than in PBMHAH (15–25 grams), darkly pigmented (brown or black nodules) and there is.

Adrenocortical nodular dysplasia with foci of eosinophilic giant cells [46]. The term PPNAD was coined by Dr J. Aidan Carney (Mayo Clinic, Rochester, Minnesota, United States) in 1984 [47]. PPNAD presents as multiple, small, pigmented nodules (~6 mm in size) with inter- nodular cortical atrophy [18]. Unlike in PMAH, the adrenal glands in PPNAD have several pathognomonic features including abnormal adrenal contour on imaging, smaller in size than in PBMHAH (15–25 grams), darkly pigmented (brown or black nodules) and there is adrenal contour on imaging, smaller in size than in PBMHAH (15–25 grams), darkly pigmented (brown or black nodules) and there is.
these two entities share several features including micronodularity, paradoxical rise of glucocorticoid excretion during the Liddle’s test (1 mg overnight and low and high dose dexamethasone suppression tests) [49], and autosomal dominant inheritance in some cases [50, 51]. On pathology, iMAD is characterized by multiple small yellow-to-dark brown nodules surrounded by a cortex with a uniform appearance, which leads to capsular deficits resulting in extra-adrenal cortical excrescences and moderate diffuse cortical hyperplasia [2, 51, 52]. This disease is highly heterogeneous, and disease-causing variants in PDE11A [52, 53], PDEB8 [10, 52], or germline duplications of PRKACA [34, 35, 54] have been implicated in its pathogenesis. Micronodular adrenocortical hyperplasias mainly produce cortisol and/or its pre-cursors, although non-cortisol producing lesions exist (unpublished data) but have not been extensively studied [15].

### Familial Syndromes Associated with Primary Adrenocortical Hyperplasia

Several monogenic disorders have been associated with the development of primary adrenocortical hyperplasias (Table 2). The following section briefly enlists these conditions.

#### Carney Complex (CNC)

CNC is an autosomal dominant multiple neoplasia syndrome arising from genetic alterations in three loci, PRKAR1A (which codes for R1α subunit of PKA and is known as the CNC1 locus), 2p16 (CNC2 locus, gene unknown) PRKACB (1p31.1, CNC3 locus) [55]. Most disease-causing variants are caused by inactivating variants in R1α of PKA that are spread along the whole coding sequence [9, 56]. The clinical manifestations of CNC include PPNAD (more than 60 % of patients with CNC have clinically detectable PPNAD), cardiac myxomas, pigmented skin lesions (lentiginosis and blue nevi), somatotroph-pituitary adenomas, LCSSCT, benign thyroid nodules, differentiated thyroid cancer, and melanocytic schwannomas. CNC does not predispose to macronodular adrenocortical hyperplasia.

#### Multiple Endocrine Neoplasia Type 1 (MEN-1)

MEN-1 is an autosomal dominant condition that arises from heterozygous disease-causing inactivating germ-line variants of MEN1 (11q13) [57]. The clinical manifestations of MEN-1 include primary hyperparathyroidism (> 95 %), skin lesions (> 90 %), pituitary adenomas (45 %), and neuroendocrine neoplasms (> 30 %). Adrenal enlargement are seen in approximately 20.4 % (146/715) of patients with MEN-1. MEN-1 may predispose to PBMAH (10.1 % of the...
It is not known if MEN-1 predisposes to micronodular adrenocortical hyperplasia.

**Familial Adenomatous Polyposis (FAP)**

FAP is an autosomal dominant condition that arise from the tumor suppressor gene APC. The clinical manifestations include large pre-cancerous colorectal polyps, primary adrenocortical lesions including PBMAH, papillary thyroid carcinomas, lipomas, and pancreatic carcinomas. PBMAH is an infrequent manifestation of FAP [22]. It is not known if FAP predisposes to micronodular adrenocortical hyperplasia.

**Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)**

HLRCC is an autosomal dominant condition arising from disease-inactivating variants of the mitochondrial enzyme fumarate hydratase (FH). Clinical manifestations include hereditary leiomyomatosis, renal cancer, and adrenal lesions. HLRCC predisposes to PMAH and/or adrenocortical adenomas that can be non-functional [22, 59, 60], although the first demonstration of FH’s involvement in adrenocortical tumors was in a patient with PBMAH and mostly subclinical hypercortisolism [59].

**Carney Triad (CT)**

CT is a sporadic condition from an unknown genetic defect with a female predominance. In CT, patients harbor a recurrent aberrant DNA methylation of the promoter region of the SDHC gene [61]. This condition predisposes to hamartomatous lesions in various organs (such as pulmonary chondromas, gastrointestinal stromal tumors, pheochromocytoma, and esophageal leiomyoma [62]. CT is the only known adrenal condition that has among its clinical manifestations both adrenocortical and medullary involvement; in fact, adrenal lesions are the fourth component of this condition, which includes PMAH and/or adrenocortical adenomas that are mostly non-functional [63].

**Genetic Classification, Testing and Counseling of Patients with Familial Primary Adrenocortical Hyperplasias**

Advances in the field of genetics and genomics has substantially progressed and informed our understanding of the molecular pathogenesis of sporadic and familial forms of primary adrenocortical hyperplasias. In keeping with the growing list of genes implicated in the pathogenesis of these lesions, and to better serve genetic testing and counseling of affected or at risk patients, a gene-based classification in which patients are grouped based on the presence of disease-causing germline variants or other genetic alterations is required (Fig. 2). This classification will highlight the causative genes, which may aid with prioritizing genetic testing and/or counseling of affected family members. Additionally, this approach may decrease the risk of misclassifying familial cases as sporadic. An example of such a classification system includes listing the implicated gene name before the type of hyperplasia, such as ARMC5-PBMAH, MEN1-PBMAH, PRKAR1A-CNC, and PDE11A-iMAD.
AD (►Fig. 2). As there are yet unidentified molecular cause(s) of these adrenocortical hyperplasias [15], we anticipate a growing number of genes implicated in these disorders over the next decades and a robust, flexible and easy to follow classification system is thus required.

Since most familial forms of adrenocortical hyperplasias are inherited in an autosomal dominant manner, establishing a causative gene is important for understanding the disease mechanisms, mode of inheritance and usefulness of cascade screening. Although the genotype-phenotype correlation is often times unpredictable, providing specific screening and counseling could decrease a patient’s anxiety towards this uncertainty, decrease genetic discrimination and ensure appropriate disease surveillance. Genetic screening may begin as early as infancy in at risk individuals, especially in CNS or iMAD from MAS. A successful patient counseling model should incorporate the patient’s values and attitudes toward their disease, while underscoring the risks and benefits of genetic screening and counseling, psychosocial interventions and service delivery [64].

In the context of ARMC5-PBMAH or PDE11A-iMAD/PBMAH, the penetrance is decreased and first-degree relatives that are carriers may not be affected. Therefore, all first-degree relatives with a known carrier state should be referred for genetic counseling and phenotype-directed biochemical screening per established clinical guidelines. Family screening of ARMC5, as with the other genes as listed in ►Table 1 and ►2, will allow early detection of carriers, and prospective follow up. Genetic testing should be offered when an individual is free to refuse or accept the test according to their wishes and moral beliefs. Children should not be tested for these low penetrant genes unless there is clinical evidence of disease.

Conclusions

The identification of several genetic causes of primary adrenocortical hyperplasias, primarily in the cAMP-signaling pathways, have paved the way for large-scale clinical and molecular studies and future research. The traditional classification as adenomas, hyperplasias and carcinomas is non-specific and has added confusion to the nomenclature of these lesions. In this new era of personalized care and genetics, a gene-based classification that is more specific is required to assist in the understanding of their disease processes, hormonal functionality and signaling pathways. Additionally, a gene-based classification carries implications for treatment, genetic counseling and screening of asymptomatic family members.

Author and Contributors

All authors contributed equally to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content; and final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding Information

This work was supported by the intramural program of the Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health (NIH), protocol HD008920. Dr. Stratakis has patents on the PRKAR1A, PDE11A, and GPR101 genes and his laboratory has recently received research funding from Pfizer Inc.

Conflict of Interest

Dr. Stratakis holds patents on the PRKAR1A, PDE11A, GPR101 genes and/or their function and his laboratory has received support from Pfizer Inc on research on GPR101 and acromegaly.

References


